Market Background: The market for continuous glucose monitors (CGMs) for non-insulin users in the United States is experiencing rapid growth, particularly with increasing demand for home healthcare devices. While existing CGMs required a prescription, the OTC approval is expected to significantly improve accessibility. Dexcom's Stelo has expanded its user base to include children aged two and older. ## Regulatory Significance: The FDA's OTC approval indicates that the device has sufficiently demonstrated its safety and accuracy. This is a strong signal that integrated CGM (iCGM) technology meets regulatory standards and may streamline the approval process for similar devices in the future. Regulatory easing will also influence the product development roadmaps of other companies. ## Patient Impact: Stelo enables children and their caregivers to actively participate in blood glucose management. Even non-insulin users can benefit from real-time data to improve their lifestyle. The device's user-friendly design and OTC availability are expected to contribute to reducing healthcare access disparities. ## Industry Implications: Dexcom has secured a new growth driver through OTC market entry with this approval. Competitors such as Abbott and Medtronic are also preparing similar products, suggesting that competition for market share will accelerate. Investors are also likely to pay attention to this regulatory success and reassess their valuations of related biodevice companies.